Lupin (LUPIN) — Announcement

📢 Key Event
Lupin receives FDA approval for Diazepam Injection USP in the United States

💡 Investor Takeaway
This approval unlocks entry into a $77.9 million U.S. anxiety treatment market segment with established demand.

Lupin Limited announced FDA approval for its generic Diazepam Injection USP in the United States, targeting the $77.9 million annual market for anxiety treatment. The filing, disclosed via NSE announcement on July 31, 2026, marks entry into a key therapeutic segment with established demand. The press release confirms bioequivalence to Hoffman-La Roche's Valium® and positions Lupin to capture share in a segment with significant revenue potential.

📄 View Original Announcement (PDF)

📊 Stock Analysis — LUPIN ✨ Ask AI About This

About Lupin Limited (LUPIN)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

Market Cap: ₹1,04,071.47 Cr P/E: 36.2

View full LUPIN stock details →

📡 Get AI alerts when LUPIN files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track LUPIN — Free

💡 Ask AI about this filing

"How will Lupin's U.S. revenue growth be impacted by this approval?" "What is Lupin's market share target for Diazepam Injection in the U.S.?" "How does this approval compare to Lupin's existing CNS portfolio performance?"

Ask AI Free →

📊 More LUPIN filings

See all LUPIN filings →

🔥 Also filed on 31 July 2026

TVVISION TV Vision Limited Announcement INDIAGLYCO India Glycols Limited Corporate Action MARUTI Maruti Suzuki India Limited Financial Results MARUTI Maruti Suzuki India Limited Financial Results KUANTUM Kuantum Papers Limited Announcement SHANKARA Shankara Building Products Limited Announcement

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when LUPIN files new disclosures

Track LUPIN filings, board meetings, and corporate actions. Free email alerts at 5 PM.